OCV C01 / Otsuka, OncoTherapy - LARVOL DELTA

Clinical Trial of a Cancer Vaccine Targeting VEGF and KIF20A in Advanced Biliary Tract Cancer. (PubMed, Anticancer Res) - "The cancer vaccine had positive effects on survival, indicating that this approach warrants further clinical studies."

Clinical • Journal • Biliary Cancer • Biliary Tract Cancer • Cholangiocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor • FLT1 • KDR • VEGFA

[VIRTUAL] PHASE II CLINICAL TRIAL USING NOVEL PEPTIDE COCKTAIL VACCINE AS A POSTOPERATIVE ADJUVANT TREATMENT FOR SURGICALLY RESECTED PANCREATIC CANCER PATIENTS (UEGW 2020) - "OCV-C01 combined with gemcitabine was tolerable with a favorable median DFS of 15.8 months. In cancer vaccine treatment, positive expression of targeted antigen was essential, and postoperative adjuvant setting was more suitable than advanced state of cancer."

Clinical • IO Biomarker • P2 data • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor • FLT1 • KDR

[VIRTUAL] PHASE II CLINICAL TRIAL USING NOVEL PEPTIDE COCKTAIL VACCINE AS A POSTOPERATIVE ADJUVANT TREATMENT FOR SURGICALLY RESECTED PANCREATIC CANCER PATIENTS (UEGW 2020) - "OCV-C01 combined with gemcitabine was tolerable with a favorable median DFS of 15.8 months. In cancer vaccine treatment, positive expression of targeted antigen was essential, and postoperative adjuvant setting was more suitable than advanced state of cancer."

Clinical • IO Biomarker • P2 data • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor • FLT1 • KDR

[VIRTUAL] PHASE II CLINICAL TRIAL USING NOVEL PEPTIDE COCKTAIL VACCINE AS A POSTOPERATIVE ADJUVANT TREATMENT FOR SURGICALLY RESECTED PANCREATIC CANCER PATIENTS (UEGW 2020) - "OCV-C01 combined with gemcitabine was tolerable with a favorable median DFS of 15.8 months. In cancer vaccine treatment, positive expression of targeted antigen was essential, and postoperative adjuvant setting was more suitable than advanced state of cancer."

Clinical • IO Biomarker • P2 data • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor • FLT1 • KDR

The development of therapeutic cancer vaccine for pancreatic cancer. (ASCO-GI 2020) - "OCV-C01 combined with gemcitabine was tolerable with a favorable median DFS of 15.8 months. In cancer vaccine treatment, positive expression of targeted antigen was essential, and postoperative adjuvant setting was more suitable than advanced state of cancer. Clinical trial information: UMIN000007991."

FLT1 • KDR • VEGFA

PHASE II CLINICAL TRIAL USING NOVEL PEPTIDE VACCINE COCKTAIL COMBINED WITH GEMCITABINE FOR SURGICALLY RESECTED PANCREATIC CANCER PATIENTS (APCM 2019) - "OCV-C01 combined with gemcitabine was tolerable, and DFS was favorably compared with previous data for resected pancreatic cancer. DFS of patients with positive KIF20A expression in resected pancreatic cancer specimen might be prolonged with frequent KIF20A-specific CTL response by receiving this immunotherapy treatment."

Clinical • IO Biomarker • P2 data